Dioun SM, et al. - In this retrospective analysis, researchers analyzed all women (n = 235) with gynecologic cancer who received pegylated liposomal doxorubicin (PLD) from 2006 to 2018, to determine the necessity of pretreatment cardiac evaluation in these patients. They assessed demographic data, treatment records, cardiac risk factors, and cardiac surveillance testing. During a median follow-up of 24 months, a median of 3 cycles of PLD with a cumulative dosage of 237 mg was received by patients. They found no significant variation in median ejection fraction in 56 patients who underwent both pre- and post-treatment cardiac testing. PLD-related cardiac toxicity was detected in 3 patients but severe manifestations necessitating PLD therapy cessation were noted in only one patient. Based on the findings, experts concluded that there may be no need of performing routine cardiac testing prior to, during or following treatment with PLD. For individual patients with high clinical suspicion of PLD-related cardiac toxicity, possible more appropriateness of cardiac testing was suggested.